Table 3. Results From Secondary Analyses That Expanded the Population by Including Patients Who Had Used Angiotensin-Converting Enzyme Inhibitors or Angiotensin Receptor Blockers in the Past 180 Days.

Variable	Ramipril (n = 8656)	Telmisartan (n = 8656)
Composite End Point
No. of person-years	10 227	8749
No. of events	799	695
Incidence rate per 1000 person-years	78.13	79.44
Unadjusted	1 [Reference]	0.96 (0.89-1.04)
PS matched	1 [Reference]	0.97 (0.88-1.08)
Stroke
No. of person-years	10 760	9098
No. of events	184	173
Incidence rate per 1000 person-years	17.1	19.01
Unadjusted	1 [Reference]	1.08 (0.92-1.27)
PS matched	1 [Reference]	1.07 (0.87-1.32)
Myocardial Infarction
No. of person-years	10 755	9132
No. of events	156	126
Incidence rate per 1000 person-years	14.5	13.8
Unadjusted	1 [Reference]	0.87 (0.72-1.04)
PS matched	1 [Reference]	0.91 (0.72-1.15)
Hospitalization for Heart Failure
No. of person-years	10 433	8928
No. of events	589	481
Incidence rate per 1000 person-years	56.46	53.88
Unadjusted	1 [Reference]	0.93 (0.84-1.02)
PS matched	1 [Reference]	0.91 (0.81-1.03)
Angioedema
No. of person-years	10 885	9220
No. of events	32	10
Incidence rate per 1000 person-years	2.94	1.08
Unadjusted	1 [Reference]	0.43 (0.23-0.82)
PS matched	1 [Reference]	0.35 (0.17-0.71)

Abbreviation: PS, propensity score.